All In Biotech

Free tool

FAERS Monitor: Welireg

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215383 or its brand name (Welireg, Belzutifan). Reports on generic versions are filed under their own applications.

Reports

1,777

Serious

1,224

69% of reports

Hospitalization

727

Death reported

167

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • anaemia329
  • malignant neoplasm progression262
  • hypoxia174
  • fatigue129
  • death80
  • dyspnoea70
  • diarrhoea66
  • haemoglobin decreased65
  • off label use65
  • oxygen saturation decreased61
  • nausea59
  • therapy interrupted57
  • drug ineffective52
  • hospitalisation51
  • pneumonia41

Reports by year received

View as table
YearReports
202139
2022315
2023388
2024179
2025234
2026622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hypoxiaSignal17458.851.09,792
malignant neoplasm progressionSignal26230.427.17,426
anaemiaSignal32920.518.56,112
oxygen saturation decreasedSignal6112.910.0656
therapy interruptedSignal579.47.3423
haemoglobin decreasedSignal657.55.9361
hospitalisationSignal513.93.0109
fatigue1292.01.762
pneumonia411.51.16
dyspnoea701.51.210
diarrhoea661.21.02
death801.10.91
nausea590.90.71
off label use650.90.71
drug ineffective520.50.433

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.